ARVO_4-30-2010.docx - NovaBay Pharmaceuticals, Inc.

workkinkajouΒιοτεχνολογία

5 Δεκ 2012 (πριν από 4 χρόνια και 11 μήνες)

249 εμφανίσεις



NovaBay Pharmaceuticals Announces New Data on First
-
in
-
Class

Anti
-
infective Compounds at ARVO Annual Meeting


EMERYVILLE, Calif.

and

HUENENBERG, Switzerland


April 30, 2010



NovaBay
Pharmaceuticals, Inc.
(AMEX:
NBY
) announced today that the latest public data on its
Aganocide
®

compounds, a new class of broad
-
spectrum antimicrobials, will be presented
during three poster sessions at the Association for Research in Vision and Ophthalmology
(ARVO) annual meeting in Fort Lauderdale, Florida.


NovaBay’s Aganocide compounds are first
-
in
-
class anti
-
infectives being developed for the
treatment and prevention of antibiotic
-
resistant infections. NovaBay and Alcon, Inc., the
world’s leading eye care company, have a licensing and research collaboration agreement
for the use of NovaBay’s Aga
nocide compounds in the eye, ear and sinus, and for contact
lens care.

The following abstracts will be presented:



In vitro

Microbicidal Activity in Tears of

N,N
-
dichloro
-
2,2
-
dimethyltaurine (NVC
-
422, AL
-
46383A), a Novel Topical Ophthalmic Agent,”



Monda
y, May 3, from 1:45 p.m. to 3:30 p.m.



Abstract Authors: Dr. Kathryn Najafi, founder and medical director of the Eye Institute of
Marin and a NovaBay advisor; Dr. Stephen Wilmarth, NovaBay advisor and a founding
member of Medical Vision Technology; and Dav
id Stroman, Ph.D., and Masood
Chowhan, Ph.D., of Alcon Laboratories, et. al.



In vitro

Evaluation of
N,N
-
dichloro
-
2,2
-
dimethyltaurine (AL
-
46383A) as an
Antiviral Agent Against Adenovirus and HSV
-
1,”




Monday, May 3, from 3:45 p.m. to 5:30 p.m.



Abstract Au
thors: Eric G. Romanowski, Kathleen Yates, and Dr. Y. Jerold Gordon of the
Charles T. Campbell Lab at the University of Pittsburgh; and David Stroman, Ph.D. of
Alcon Laboratories., et. al.


“Topical
N,N
-
dichloro
-
2,2
-
dimethyltaurine (AL
-
46383A) Inhibits
Adenovirus
Replication in the Ocular Ad5/NZW Rabbit Replication Model,”




Thursday, May 6, from 2:45 p.m. to 3 p.m.



Abstract Authors: Dr. Y. Jerold Gordon, Kathleen A. Yates and Eric G. Romanowski

of the
Charles T. Campbell Lab at the University of
Pittsburgh et. al. and David Stroman, Ph.D.,
of Alcon Laboratories


Abstracts of the presentations may be accessed at
www.arvo.org
.


NVC
-
422, or AL
-
46383A, is a stable compound based on the chemical structures of
N
-
chloro
taurine (NCT) and
N,N
-
dichlorotaurine, which are naturally occurring antimicrobial
agents produced by the body’s white blood cells to fight invasive pathogens.


Alcon is conducting a Phase 2 clinical trial of this compound for the treatment of viral
conjun
ctivitis, a form of “pink eye”. The randomized, placebo
-
controlled trial is enrolling
approximately 250 patients at more than 30 medical centers in the United States and
worldwide. It is designed to determine the safety and efficacy of NVC
-
422 or AL
-
46383A
.


About NovaBay’s Aganocide
®

Compounds

The Aganocide
®

compounds are novel, proprietary, synthetic
N
-
chlorinated antimicrobial
molecules specifically developed by NovaBay to mimic the body’s natural defense against
infection. The Aganocide compounds maintain biological activities while improving the
stability of naturally occurring
N
-
chlorinated antimicro
bial molecules. These highly
differentiated, first
-
in
-
class, small molecule, patented new chemical entities may deliver the
same or better efficacy than currently used antibiotics without contributing to the growing
rise of antibiotic
-
resistant bacterial s
trains. In preclinical testing, the Aganocide compounds
have been shown to be highly effective against bacteria, including its multi
-
drug resistant
strains (such as MRSA), viruses and fungi. They also have been demonstrated to be
effective against bacteria

in biofilm, which render most antibiotics ineffective. The
Aganocide compounds have a broad therapeutic index while providing a high degree of
potency and tolerability as well as dosing versatility and flexibility.


About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing
its proprietary and patented Aganocide
®

compounds, which are novel, synthetic anti
-
infective product candidates with equivalent activity to the active antimicrobial mol
ecules
generated within white blood cells. NovaBay’s Aganocide compounds are being developed to
treat and prevent a wide range of infections without causing bacterial resistance. NovaBay
has internal development programs aimed at addressing hospital and re
spiratory infections.
The company has a license and research collaboration agreement with Alcon for use of its
Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care.
NovaBay has also entered into an agreement with Gald
erma S.A. to develop and
commercialize Aganocide compounds in acne, impetigo and other dermatological
indications. For more information on NovaBay, visit:
www.novabaypharma.com
.


Cautionary Information Regarding For
ward
-
Looking Statements

This release contains forward
-
looking statements, which are based upon management’s
current expectations, assumptions, estimates, projections and beliefs. . Words such as
"believe," "expect," "may" and other words and variations o
f these words implying future
events, identify these statements as forward
-
looking statements. Statements regarding
NovaBay’s expectations
on
the potential efficacy of the Aganocide compounds as well as
other statements that relate to future results are
forward
-
looking statements. Forward
-
looking statements involve known and unknown risks, uncertainties and other factors that
may cause actual results or achievements to be materially different and adverse from those
expressed in or implied by the forward
-
l
ooking statements. Other risks relating to NovaBay
and its Aganocide compounds, including risks that could cause results to differ materially
from those projected in the forward
-
looking statements in this press release, are detailed in
NovaBay’s Annual Rep
ort on Form 10
-
K for the period ended December 31, 2009, under the
caption "Risk Factors" in Item 1A of Part I of that report, filed with the Securities and
Exchange Commission on March 29, 2010. The forward
-
looking statements in this release
speak only as

of this date, and NovaBay disclaims any intent or obligation to revise or
update publicly any forward
-
looking statement except as required by law.


###



NovaBay Pharmaceuticals, Inc. Contact Information:


Investors






Thomas J. Paulson





Chief
Financial Officer




510
-
899
-
8809





tpaulson@novabaypharma.com




Media

Susan L. Thomas

Director of Corporate Communications


510
-
899
-
8841

sthomas@novabaypharma.c
om